Skip to main content
Log in

sQuiz your knowledge! Itchy, polymorphic skin lesions in a patient with clear cell renal carcinoma

  • Residents’ Corner
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345–61.

    Article  Google Scholar 

  2. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017; 8:49.

    Article  CAS  Google Scholar 

  3. Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 2018; 57:664–9.

    Article  CAS  Google Scholar 

  4. Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79: 1081–8.

    Article  CAS  Google Scholar 

  5. Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist 2018;23:1119–26.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jacek C. Szepietowski.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wójcik, E., Stefaniak, A. & Szepietowski, J.C. sQuiz your knowledge! Itchy, polymorphic skin lesions in a patient with clear cell renal carcinoma. Eur J Dermatol 30, 769–770 (2020). https://doi.org/10.1684/ejd.2020.3938

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3938

Navigation